Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Exelixis
Biotech
Exelixis beats Bayer drug in cancer trial, sending stock higher
The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.
Nick Paul Taylor
Jun 23, 2025 7:30am
Exelixis drops ADC after deciding it's no match for Tivdak
Aug 7, 2024 5:22am
Exelixis lays off 175 employees in refocus on emerging pipeline
Jan 8, 2024 6:10am
Exelixis dips into the AI game, LIB cashes in on PCSK9
Sep 12, 2023 11:00am
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
Eikon builds out clinical development team—Chutes & Ladders
Jun 2, 2023 9:30am
